Liquidia Co. (NASDAQ:LQDA) Receives Average Recommendation of “Buy” from Analysts

Liquidia Co. (NASDAQ:LQDA) has been given a consensus recommendation of “Buy” by the nine analysts that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $25.38.

A number of analysts have weighed in on the company. Scotiabank assumed coverage on Liquidia in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 price target for the company. Wells Fargo & Company assumed coverage on Liquidia in a research report on Friday, December 20th. They issued an “overweight” rating and a $20.00 price target for the company. Lifesci Capital initiated coverage on Liquidia in a research report on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 price target for the company. Needham & Company LLC reissued a “buy” rating and set a $19.00 price objective on shares of Liquidia in a research report on Thursday. Finally, HC Wainwright reissued a “buy” rating and set a $29.00 price objective on shares of Liquidia in a research report on Thursday, November 14th.

Liquidia Price Performance

Shares of NASDAQ:LQDA opened at $12.19 on Friday. Liquidia has a fifty-two week low of $8.26 and a fifty-two week high of $16.99. The business has a 50-day moving average of $11.13 and a two-hundred day moving average of $11.04. The stock has a market capitalization of $1.03 billion, a P/E ratio of -7.48 and a beta of 0.23.

Insider Buying and Selling at Liquidia

In related news, CEO Roger Jeffs sold 8,053 shares of the stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $11.11, for a total transaction of $89,468.83. Following the sale, the chief executive officer now directly owns 812,193 shares in the company, valued at $9,023,464.23. This represents a 0.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Rajeev Saggar sold 2,526 shares of the stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $11.19, for a total value of $28,265.94. Following the sale, the insider now owns 204,857 shares in the company, valued at approximately $2,292,349.83. This trade represents a 1.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 22,007 shares of company stock valued at $245,780 in the last quarter. Corporate insiders own 30.10% of the company’s stock.

Institutional Investors Weigh In On Liquidia

Large investors have recently bought and sold shares of the business. Quest Partners LLC bought a new position in Liquidia in the 2nd quarter valued at $27,000. Clear Harbor Asset Management LLC bought a new position in Liquidia in the 3rd quarter valued at $100,000. Signaturefd LLC boosted its position in Liquidia by 38,400.0% in the 3rd quarter. Signaturefd LLC now owns 10,010 shares of the company’s stock valued at $100,000 after buying an additional 9,984 shares during the last quarter. Ballentine Partners LLC bought a new position in Liquidia in the 3rd quarter valued at $110,000. Finally, Whitcomb & Hess Inc. boosted its position in Liquidia by 10.2% in the 3rd quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company’s stock valued at $116,000 after buying an additional 1,074 shares during the last quarter. 64.54% of the stock is currently owned by institutional investors.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).